1. Overview of this issue: pharmacovigilance, what is new?

   • Linda Gore Martin
   • Yolande Hanssens
   • Vibhu Paudyal

   Editorial 21 August 2018 Pages: 737 - 739

2. The role and strategy of ISoP in global pharmacovigilance

   • Sten Olsson
   • Mira Harrison-Woolrych

   Commentary 02 August 2018 Pages: 740 - 743

   

3. An historical overview over Pharmacovigilance

   • Giulia Fornasier
   • Sara Francescon
   • Paolo Baldo

   Commentary Open access 15 June 2018 Pages: 744 - 747

   

4. Pharmacovigilance workflow in Europe and Italy and pharmacovigilance terminology

   • Paolo Baldo
   • Sara Francescon
   • Giulia Fornasier

   Commentary Open access 09 August 2018 Pages: 748 - 753

   

5. Current trends in pharmacovigilance: value and gaps of patient reporting

   • Pedro Inácio
   • Afonso Cavaco
   • Marja Airaksinen

   Commentary 13 July 2018 Pages: 754 - 757

6. Pharmacovigilance in developing countries (part I): importance and challenges

   • Shaimaa Elshafie
   • Iman Zaghloul
   • Anne Marie Roberti

   Commentary 16 December 2017 Pages: 758 - 763

   

7. Pharmacovigilance in developing countries (part II): a path forward

   • Shaimaa Elshafie
   • Anne Marie Roberti
   • Iman Zaghloul

   Commentary 10 January 2018 Pages: 764 - 768

   

8. Overview of pharmacovigilance practices at the largest academic healthcare system in the State of Qatar

   • Moza Al Hail
   • Wessam Elkassem
   • Derek Stewart

   Commentary 03 April 2018 Pages: 769 - 774

   

9. The role of the suspicious renal pharmacist in identifying unusual adverse drug reactions—why this is not a small problem

   • Carolyn Vera Coulter

   Commentary 01 June 2018 Pages: 775 - 777

10. EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies

    • Sara Francescon
    • Giulia Fornasier
    • Paolo Baldo

    Commentary Open access 09 August 2018 Pages: 778 - 782

11. Learning the effects of psychotropic drugs during pregnancy using real-world safety data: a paradigm shift toward modern pharmacovigilance

    • Angela Lupattelli
    • Olav Spigset
    • Hedvig Nordeng

    Commentary Open access 15 June 2018 Pages: 783 - 786

12. Is pharmacovigilance of biologicals cost-effective?

    • Barbara Claus

    Commentary 26 July 2018 Pages: 787 - 789

13. Pharmacovigilance in a rare disease: example of the VIGIAPATH program in pulmonary arterial hypertension

    • Marie-Camille Chaumais
    • Caroline O’Connell
    • David Montani

    Commentary 13 August 2018 Pages: 790 - 794

    

14. Targeted therapies and adverse drug reactions in oncology: the role of clinical pharmacist in pharmacovigilance

    • G. Fornasier
    • M. Taborelli
    • P. Baldo

    Research Article Open access 21 May 2018 Pages: 795 - 802

15. Finasteride use during pregnancy and early neonatal outcome: a case report

    • Doua AlSaad
    • Ben H. Lee
    • Sawsan Al-Obaidly

    Commentary 01 June 2018 Pages: 803 - 805

16. Potential negative impact of informing patients about medication side effects: a systematic review

    • Jimmy Jose
    • Lamia AlHajri

    Review Article 23 August 2018 Pages: 806 - 822

    

17. Pharmacovigilance in China: development and challenges

    • Ying Zhao
    • Tiansheng Wang
    • Shusen Sun

    Review Article 26 July 2018 Pages: 823 - 831

    

18. Pharmacovigilance in oncology

    • Paolo Baldo
    • Giulia Fornasier
    • Sara Francescon

    Review Article Open access 01 August 2018 Pages: 832 - 841

    

19. Reporting adverse drug reactions: contribution, knowledge and perception of German pharmacy professionals

    • Anna Laven
    • Katharina Schmitz
    • Wilhelm-Hubertus Franzen

    Research Article 16 June 2018 Pages: 842 - 851

    

20. Using a cancer registry to capture signals of adverse events following immune and targeted therapy for melanoma

    • João P. Aguiar
    • Fábio Cardoso Borges
    • Filipa Alves da Costa

    Research Article 02 June 2018 Pages: 852 - 861

    

21. Development and validation of an algorithm to identify drug-induced anaphylaxis in the Beijing Pharmacovigilance Database

    • Ying Zhao
    • Haidong Lu
    • Tiansheng Wang

    Research Article 20 February 2018 Pages: 862 - 869

22. Kidney function and use of nonsteroidal anti-inflammatory drugs among elderly people: a cross-sectional study on potential hazards for an at risk population

    • Sara Modig
    • Sölve Elmståhl

    Research Article Open access 19 February 2018 Pages: 870 - 877

23. Community pharmacists’ knowledge and perspectives of reporting adverse drug reactions in Australia: a cross-sectional survey

    • Raymond Li
    • Colin Curtain
    • Syed Tabish Razi Zaidi

    Research Article Open access 10 August 2018 Pages: 878 - 889

    

24. Prevalence and characteristics of hospital inpatients with reported fluoroquinolone allergy

    • Geoffrey C. Wall
    • Matthew J. Taylor
    • Hayden L. Smith

    Research Article 14 March 2018 Pages: 890 - 894

    

25. Healthcare professionals’ knowledge, attitude and practice towards adverse drug reaction (ADR) reporting at the health center level in Ethiopia

    • Mohammed Assen Seid
    • Asmamaw Emagn Kasahun
    • Saron Naji Gebremariam

    Research Article 09 August 2018 Pages: 895 - 902

    

26. Comparison of different methods for causality assessment of adverse drug reactions

    • Sapan Kumar Behera
    • Saibal Das
    • Selvarajan Sandhiya

    Research Article 26 July 2018 Pages: 903 - 910

    

27. Trends in reporting drug-associated liver injuries in Taiwan: a focus on amiodarone

    • Jun-Hong Ye
    • Yunn-Fang Ho
    • Yun-Wen Tang

    Research Article 26 July 2018 Pages: 911 - 920

    

28. Traditional Chinese medicine and drug-induced anaphylaxis: data from the Beijing pharmacovigilance database

    • Xiaotong Li
    • Sydney Thai
    • Tiansheng Wang

    Research Article 26 July 2018 Pages: 921 - 927

29. Cardiovascular and gastrointestinal safety of selective cyclooxygenase-2 inhibitors: a case/non-case study

    • Luis Hermenegildo Martin Arias
    • Antonio Martin Gonzalez
    • Maria Sainz

    Research Article 31 July 2018 Pages: 928 - 935